Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2022.555 | RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial | Prof. WONG Ronald Man Yeung |
| 2021.384 | Prevalence of Ostersarcopenia in Fragility Fracture Patients |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2021.478 | A multicentre retrospective study on the clinical and radiological features, and outcome of surgical treatment in Atypical Femoral Fractures in Hong Kong |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2022.079 | Sarcopenia in Hip Fracture Patients |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2023.401 | RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial | Prof. WONG Ronald Man Yeung |
| 2021.622 | Fracture Liaison Services For Osteoporotic Fracture |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2021.488 | Detection of Clinically Silent Vertebral Fractures with Vertebral Fracture Assessment on a Fracture Liaison Service in a Chinese Population |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2022.256 | Artificial Intelligence in Detection of Vertebral Compression Fracture |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2017.447 | Vibration Therapy as a Rehabilitation Intervention for Postural Training and Fall Prevention after Distal Radius Fracture in Elderly Patients: A Randomized Controlled Trial | Dr. WONG Ronald Man Yeung |
| 2016.391 | A study to evaluate the effectiveness of a structured patient education on patient discharge in Department of Medicine and Therapeutics, Prince of Wales Hospital |
Ms. WONG Rebecca Yee Man 黃綺文 |
| 2009.087 | Peer Leaders Accelated Training Initiative to Unlash Potential of mentorship (PLATINUM) Program: A feasibility study on a train-the-trainer course on peer support for people with type 2 diabetes | Ms WONG Rebecca Y M |
| 2012.406 | A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | Dr. Wong Raymond Siu-Ming |
| 2010.159 | A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults, with chronic immune (idiopathic) thrombocytopenic purpura(ITP) | Dr. WONG Raymond Siu Ming |
| 2019.158 | An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor-Naive or Have Not Recently Received Complement Inhibitor Therapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.225 | A phase 3, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.160 | A Phase 3, Multicenter, Open-Label, Single-Arm Study to Confirm the Safety and Efficacy of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.392 | Molecular study of essential thrombocythaemia with next generation sequencing to identify prognostic markers in Chinese population | Dr. WONG Raymond Siu Ming |
| 2022.652 | A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations (BELLWAVE-008) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.493 | A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.567 | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.641 | A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.347 | Molecular study of myelofibrosis with next generation sequencing to identify prognostic markers and to evaluate applicability of prognostic models in Chinese population |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2016.463 | A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2016.534 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2015.010 | The hepato-protective effects of umbilical cord-derived stem cell on acetaminophen induced liver injury. | Dr. WONG Raymond Siu Ming |
| 2015.506 | A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) – CHRONOS-3 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2014.635 | Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world | Dr. WONG Raymond Siu Ming |
| 2016.631 | A Phase IV multicenter, observational study in Chronic Immune Thrombocytopenia patients on eltrombopag treatment in emerging markets (CITE Study) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2016.400 | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma. |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2017.002 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2015.670 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2013.608 | An open-label, single-arm, Phase Ib/II study of AEB071 (a protein kinase C inhibitor) and everolimus (mTOR inhibitor) in patients with CD79-mutant or ABC subtype diffuse large B-cell lymphoma | Dr. WONG Raymond Siu Ming |
| 2015.087 | Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas (Part B) | Dr. WONG Raymond Siu Ming |
| 2016.688 | Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) Including Those with the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment with a B-Cell Receptor Inhibitor |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2017.452 | A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH). – PADDOCK – |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2016.178 | A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non-Hodgkin Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2016.399 | A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2015.579 | A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults with Thrombotic Microangiopathies |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2015.580 | A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2015.147 | A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2017.267 | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2014.269 | A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndrome (MDS) | Dr. WONG Raymond Siu Ming |
| 2019.229 | Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed/Refractory Multiple Myeloma in Asia Pacific |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2020.576 | A Study to Describe the Real-world Use of Dasatinib Treatment for Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukaemia (CML) | Dr. WONG Raymond Siu Ming |
| 2020.156 | A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2018.471 | An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of PEGCETACOPLAN in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.481 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF REGN3918 IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Dr. WONG Raymond Siu Ming |
| 2019.286 | A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.512 | A retrospective analysis of risk factors and outcomes of cancer-associated venous thromboembolism in Chinese patients | Dr. WONG Raymond Siu Ming |
| 2020.692 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITANT JAK2 INHIBITOR THERAPY AND WHO REQUIRE RED BLOOD CELL TRANSFUSIONS The “INDEPENDENCE” Trial |
Dr. WONG Raymond Siu Ming 王紹明 |
Page 28 of 262.